BIOMAT Database Logo BIOMAT Database Logo

Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens. 2006

Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

Estrogen receptor alpha (ERalpha) is a ligand-inducible transcription factor that mediates the biological effects of estrogens and antiestrogens. Many point mutations in the human ERalpha gene have been reported to be associated with breast cancer, endometrial cancer, and psychiatric diseases. However, functional analyses for most mutants with amino acid changes are still lacking. In the present study, to investigate the effects of point mutations on the function, gel-shift assays and luciferase assays were performed for eight kinds of mutated ERalpha proteins, including a single nucleotide change of C207G (N69K), G478T (G160C), T887C (L296P), A908G (K303R), C926T (S309F), A1058T (E353V), A1186G (M396V), and G1231deletion (411fsX7). The mutated ERalpha expression plasmids were constructed by site-directed mutagenesis. With gel-shift assays using in vitro translated ERalpha proteins, binding to the consensus estrogen response element (ERE) was observed for the mutated ERalpha proteins except ERalpha (G160C) and ERalpha (411fsX7), the binding of which was comparable with that of the wild type. Western blot analyses showed that ERalpha (G160C) could not be efficiently translated with the in vitro transcription/translation system and that ERalpha (411fsX7) produced a truncated protein. To investigate the transactivation potency, wild-type or mutated ERalpha expression plasmids were co-transfected with pGL3-3EREc38 reporter plasmid into human breast adenocarcinoma MDA-MB-435 cells. The concentration-response curves (10pM-100nM E2) of the mutant ERalpha proteins except ERalpha (E353V) and ERalpha (411fsX7) were similar to that of wild-type ERalpha. However, at a low level of E2 (100pM), the mutants ERalpha (N69K), ERalpha (L296P), ERalpha (S309F), and ERalpha (M396V) showed a significant decrease of transactivation compared with that of the wild-type ERalpha. The mutants ERalpha (E353V) and ERalpha (411fsX7) did not show responsiveness to E2 and antiestrogens, 4-hydroxytamoxifen (4OHT) and ICI 182,780. The mutant ERalpha (S309F) showed decreased responsiveness for the antiestrogenicity of 4OHT. In conclusion, we found that some of the naturally occurring human ERalpha mutants with amino acid changes may have an altered responsiveness to estrogen and antiestrogens.

UI MeSH Term Description Entries
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription

Related Publications

Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
March 1996, Molecular endocrinology (Baltimore, Md.),
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor.
June 1994, The Journal of steroid biochemistry and molecular biology,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.
February 1999, Endocrinology,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells.
January 2007, The Journal of steroid biochemistry and molecular biology,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.
January 2004, Cellular and molecular life sciences : CMLS,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha.
May 2007, Molecular cancer therapeutics,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements.
March 1999, Biochemical pharmacology,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha.
June 2002, Biochemistry,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
The stability of the uterine estrogen receptor when complexed with estrogens or antiestrogens.
November 1980, Molecular pharmacology,
Sayaka Komagata, and Miki Nakajima, and Yuki Tsuchiya, and Miki Katoh, and Ryoichi Kizu, and Satoru Kyo, and Tsuyoshi Yokoi
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
May 1996, Cancer research,
Copied contents to your clipboard!